We use cookies for a better user experience. Read our Privacy Policy

I Agree

Breast Cancer Diagnostics Market

Breast Cancer Diagnostics Market (Technique: Imaging, Tissue Biopsy Tests, and Molecular Testing; Cancer Type: Ductal Carcinoma In Situ [DCIS] and Invasive Breast Cancer; and End User: Hospitals & Ambulatory Surgery Centers, Diagnostic Laboratories, and Research & Academic Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

AI Systems with Advanced Analytics to Identify Unmet Patient Needs

Breast cancer is one of the most common types of cancer found in women worldwide. However, breast cancer does not always show obvious symptoms in the early stages. Hence, companies in the breast cancer diagnostics market are increasing their R&D in AI technologies to identify unmet patient needs. For instance, Paragon Biosciences LLC announced the launch of its seventh portfolio company Qlarity Imaging LLC, to gain FDA clearance for their AI system used for breast cancer diagnostics in radiology.

Companies in the breast cancer diagnostics market are harnessing the advantages of AI to improve medical outcomes. The AI technology is being increasingly used in additional image modalities with the goal of lowering costs for hospitals as well as payers. Companies in the market for breast cancer diagnostics are directing their investments in developing AI systems with intuitive displays and machine learning (ML).

breast cancer diagnostics market infographic

To know the scope of our report Get a Sample on Breast Cancer Diagnostics Market

Blood Screening Tests Revolutionize Breast Cancer Diagnostics with Early Detection Possibilities

Most types of breast cancer are treatable and survival rates are high for patients that detect cancer at an early stage. Hence, researchers in the market for breast cancer diagnostics are increasing their focus in novel methods of blood screening that are reinventing techniques for early detection of breast cancer. For instance, researchers from the University of Nottingham are innovating in new blood screening methods that can help detect breast cancer years before it gets severe. Such discoveries are bolstering market growth, as the breast cancer diagnostics market is expected to reach a revenue of ~US$ 9 Bn by the end of 2027. Moreover, molecular testing is anticipated for exponential growth during the forecast period.

On the other hand, researchers are examining antigens and auto-antibodies to determine the presence of a tumor. Tumor-associated antigens (TAAs) are considered as a reliable indicator of breast cancer. Thus, companies in the breast cancer diagnostics market should collaborate with researchers to advance in clinical studies.

Get a glimpse of the in-depth analysis through our Report Brochure

Simplifying Synthesis Steps and Nanoprobe Functionalization Bolster Innovations in Nanotechnology

Nanotechnology holds promising potential for early detection of breast cancer. This technology is being highly publicized for its high sensitivity, specificity, and multiplexed measurement capacity in the breast cancer diagnostics market. However, translation of nanotechnology-based diagnostic methods into routine clinical applications poses as a challenge for healthcare providers.

The breast cancer diagnostics market is consolidated with three major players accounting for ~66% of the global market share. This indicates that companies are increasing their research efforts in new diagnostic methods such as nanotechnology and deep learning to improve clinical numbers. However, the reliability of nanotechnology-based cancer diagnosis in regular clinical practices is still at the nascent stage in the market for breast cancer diagnostics. Moreover, high costs associated with the long-term storage of nanoprobes that are highly sensitive is another barrier for market growth. Hence, companies in the market for breast cancer diagnostics are simplifying the synthesis steps and nanoprobe functionalization and are increasing R&D to launch cost-efficient ways of introducing nanotechnology-based diagnosis in clinical practices.

Automated Diagnosis Techniques with ML Algorithms Help Distinguish Tumors

Automated breast cancer diagnostics based on ML algorithms are bringing about a change in the market landscape. Soft computing techniques are being increasingly used to produce accurate and faster diagnosis of breast cancer amongst patients. Hence, healthcare companies in the breast cancer diagnostics market are collaborating with researchers to combine imaging techniques with ML algorithms to increase diagnosis accuracy. Preprocessing, feature extraction, and classification are becoming the key focus points for healthcare companies in order to advance in ML-based imaging techniques.

Several data mining and ML techniques are being used to facilitate careful interpretation and analysis of peripheral areas of the patient. As such, feature extraction plays a pivotal role in breast cancer detection using ML techniques. Such novel techniques are helping practitioners in the breast cancer diagnostics market to distinguish between benign and malignant tumors. Transform-based texture analysis techniques are being facilitated to convert the image into new analysis studies using spatial frequency properties.

breast cancer diagnostics market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

AI-assisted technologies have become the frontrunner for innovations in the breast cancer diagnostics market. Thus, the market is expected to expand at a favorable CAGR of ~7% during the forecast period. Precision medicines and personalized therapies are helping to improve clinical numbers. Since ‘cancer’ is commonly associated as an ‘expensive disease’, healthcare companies are increasing their R&S activities to boost the availability of affordable tests and treatments.

ML techniques are gaining prominence in mammographic imaging of regions of interest (ROIs). However, there is a need for more confined approach toward the detection of cancerous lesions in conventional ML studies. Hence, companies should increase focus in architecture distortion and the detection of bilateral asymmetry to innovate in mammographic imaging.

Breast Cancer Diagnostics Market: Overview

  • The global breast cancer diagnostics market was valued at US$ 4.8 Bn in 2018 and is projected to expand at a high CAGR from 2019 to 2027. High prevalence and increase in incidence rate of breast cancer across the globe and technological advancements in diagnostic techniques are anticipated to fuel the growth of the global breast cancer diagnostics market.
  • Breast cancer is the most common form of cancer observed among women across the globe and accounts for around 12.3% of all the cancer cases reported. Breast cancer starts in breast tissues when the cells in the breast begin to grow out of control.
  • Breast cancer starts in the milk ducts that carry milk to the nipple. It could also start in the milk glands and other tissues of the breast. Symptoms of breast cancer are the formation of new lump or mass in the breast, swelling, pain, and nipple retraction. The two basic types of breast cancer are invasive breast cancer and non-invasive breast cancer. Around 80% of breast cancers are invasive.
  • Breast cancer can be diagnosed using different techniques, from physical examination to CT/PET scan. Mammography systems are used as the first line of diagnosis of breast cancer. The other breast cancer diagnostic tools are breast ultrasound systems, breast magnetic resonance imaging, computed tomography (CT scan), positron emission tomography (PET scan), breast biopsy, and molecular testing.
  • The global breast cancer diagnostics market is expected to be driven by high prevalence and increase in incidence rate of breast cancer across the globe. According to the World Cancer Research Fund Organization, 2,088,849 cases of breast cancer were reported globally in 2018. The organization estimated that the number of breast cancer cases would reach to 5.5 million across the world by the end of 2030.
  • Presently, R&D on cancer diagnosis is primarily focused on liquid biopsy. Market players and research institutes are conducting extensive clinical trials to develop highly sensitive biopsy platform. In May 2018, Grail, a U.S.-based biotechnology company, raised US$ 1 Bn in VC funding and embarked on a 120,000-patient study for early breast cancer detection. Extensive research on biopsy aimed at promoting early diagnosis of cancer is likely to drive the global breast cancer diagnostics market during the forecast period.

Breast Cancer Diagnostics Market: Segmentation

  • The global breast cancer diagnostics market has been segmented based on technique, cancer type, end user, and region
  • In terms of technique, the global breast cancer diagnostics market has been categorized into imaging, breast biopsy tests, and molecular testing. The imaging segment is projected to lead the global breast cancer diagnostics market during the forecast period. Imaging tests are most preferred for the initial diagnosis of breast cancer and are comparatively costlier than other tools. This can be attributed to the segment’s market dominance in 2018. The imaging segment has been classified into mammography systems, breast ultrasound systems, MRI scan, and PET/CT scan.
  • Based on cancer type, the global breast cancer diagnostics market has been bifurcated into ductal carcinoma in situ (DCIS) and invasive breast cancer. The invasive breast cancer segment accounted for the largest share of the global market in 2018 and the trend is anticipated to continue during the forecast period.
  • In terms of end user, the global breast cancer diagnostics market has been divided into hospitals & ambulatory surgery centers, diagnostic laboratories, and research & academic institutes. The hospitals & ambulatory surgery centers segment dominated the global breast cancer diagnostics market in 2018 and the trend is expected to continue from 2019 to 2027.

Breast Cancer Diagnostics Market: Regional Segmentation

  • In terms of region, the global breast cancer diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global market in 2018 and is likely to gain market share by the end of 2027. The region’s dominance in terms of market share can be attributed to high prevalence and increase in incidence of breast cancer in the U.S. and Canada, and well-established healthcare facilities. High per capita healthcare expenditure, favorable medical reimbursement policies, and early adoption of technologically advanced products are attributed to the region’s large share of the global breast cancer diagnostics market in 2018.
  • Asia Pacific is projected to be the fastest growing market for breast cancer diagnostics during the forecast period. Japan dominated the market in the region in 2018. The market in India is anticipated to expand at a high CAGR during the forecast period.
  • The breast cancer diagnostics market in Latin America and Middle East & Africa is expected to expand at a high CAGR, owing to increase in demand for early diagnosis of breast cancer and focus of manufacturers on addressing unmet medical needs.

Breast Cancer Diagnostics Market: Major Players

  • Companies such as Siemens Healthineers, GE Healthcare, and Hologic, Inc. accounted for major share of the global breast cancer diagnostics market in 2018. Other global players in the market include
    • Abbott Laboratories
    • Koninklijke Philips N.V., C. R. Bard, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holding Corporation
    • Leica Biosystems Nussloch GmbH
    • bioTheranostics, Inc.
    • Myriad Genetics, Inc.
  • These players focus on adopting organic and inorganic growth strategies to strengthen product portfolio. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographic footprint, investment in research & development, and manufacture of novel breast cancer diagnostic tools in order to be competitive in the global breast cancer diagnostics market.

Breast Cancer Diagnostics Market – Segmentation

Technique

Imaging

  • Mammography
  • Analog Mammography
  • Digital Mammography
  • Breast Ultrasound System
  • MRI Scan
  • PET/CT Scan

Tissue Biopsy Tests

Molecular Testing

Cancer Type

Ductal Carcinoma In Situ (DCIS)

Invasive Breast Cancer

  • Invasive Ductal Carcinoma
  • Invasive Lobular Carcinoma
  • Metastatic Breast Cancer
  • Others

End User

Hospitals & Ambulatory Surgery Centers

Diagnostic Laboratories

Research & Academic Institutes

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Breast Cancer Diagnostics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of breast cancer diagnostics market?

Breast cancer diagnostics market to reach valuation of ~US$ 9 Bn by 2027

What is the anticipated CAGR of the breast cancer diagnostics market in the forecast period?

Breast cancer diagnostics market is expected to expand at a favorable CAGR of ~7% during 2019 - 2027

What are the key driving factors for the growth of the breast cancer diagnostics market?

Breast cancer diagnostics market is driven by high prevalence and increase in incidence rate of breast cancer across the globe

Which region is expected to project the highest market share in the global breast cancer diagnostics market?

North America accounted for a major share of the global breast cancer diagnostics market in 2018 and the trend is projected to continue during the forecast period

Who are the key players in the breast cancer diagnostics market?

Key players in the breast cancer diagnostics market include Abbott Laboratories, Koninklijke Philips N.V., C. R. Bard, Inc., F. Hoffmann-La Roche Ltd., Fujifilm Holding Corporation, Leica Biosystems Nussloch GmbH

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Breast Cancer Diagnostics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Breast Cancer Diagnostics Introduction

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Breast Cancer Diagnostics Market Analysis and Forecast, 2018–2028

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Technological Advancements

    5.2. Breast Cancer Epidemiology, by Key Countries/Region

    5.3. Breast Cancer Epidemiology

6. Global Breast Cancer Diagnostics Market Analysis and Forecast, by Technique 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Technique, 2018–2028

        6.3.1. Imaging

            6.3.1.1. Mammography

                6.3.1.1.1. Analog Mammography

                6.3.1.1.2. Digital Mammography

                6.3.1.1.3. Breast Ultrasound System

                6.3.1.1.4. MRI Scan

                6.3.1.1.5. PET/CT Scan

        6.3.2. Tissue Biopsy Tests

        6.3.3. Molecular Testing

    6.4. Market Attractiveness Analysis, by Technique 

7. Global Breast Cancer Diagnostics Market Analysis and Forecast, by Cancer Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Cancer Type, 2018–2028

        7.3.1. Ductal Carcinoma In Situ (DCIS) 

        7.3.2. Invasive Breast Cancer

            7.3.2.1. Invasive Ductal Carcinoma

            7.3.2.2. Invasive Lobular Carcinoma

            7.3.2.3. Metastatic Breast Cancer

            7.3.2.4. Others

    7.4. Market Attractiveness Analysis, by Cancer Type

8. Global Breast Cancer Diagnostics Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by End-user, 2018–2028

        8.3.1. Hospitals & Ambulatory Surgery Center

        8.3.2. Diagnostic Laboratories

        8.3.3. Research & Academic Institutes

    8.4. Market Attractiveness Analysis, by End-user

9. Global Breast Cancer Diagnostics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness Analysis, by Country/Region

10.  North America Global Breast Cancer Diagnostics Market Analysis and Forecast

    10.1. Introduction

    10.2. Key Findings

    10.3. Market Value Forecast, by Technique, 2018–2028

        10.3.1. Imaging

            10.3.1.1. Mammography

                10.3.1.1.1. Analog Mammography

                10.3.1.1.2. Digital Mammography

            10.3.1.2. PET/CT Scan

        10.3.2. Tissue Biopsy Tests

        10.3.3.  Molecular Testing

    10.4.  Market Value Forecast, by Cancer Type, 2018–2028

        10.4.1. Ductal Carcinoma In Situ (DCIS) 

        10.4.2.  Invasive Breast Cancer

            10.4.2.1. Invasive Ductal Carcinoma

            10.4.2.2.  Invasive Lobular Carcinoma

            10.4.2.3.  Metastatic Breast Cancer

            10.4.2.4.  Others

    10.5.  Market Value Forecast, by End-user, 2018–2028

        10.5.1. Hospitals & Ambulatory Surgery Center

        10.5.2.  Diagnostic Laboratories

        10.5.3.  Research & Academic Institutes

    10.6.  Market Value Forecast, by Country, 2018–2028

        10.6.1. U.S.

        10.6.2.  Canada

    10.7.  Market Attractiveness Analysis 

        10.7.1. By Technique 

        10.7.2.  By Cancer Type

        10.7.3.  By End-user

        10.7.4.  By Country

11. Europe Global Breast Cancer Diagnostics Market Analysis and Forecast

    11.1. Introduction

    11.2. Key Findings

    11.3. Market Value Forecast, by Technique, 2018–2028

        11.3.1. Imaging

            11.3.1.1. Mammography

                11.3.1.1.1. Analog Mammography

                11.3.1.1.2. Digital Mammography

            11.3.1.2. PET/CT Scan

        11.3.2. Tissue Biopsy Tests

        11.3.3.  Molecular Testing

    11.4.  Market Value Forecast, by Cancer Type, 2018–2028

        11.4.1. Ductal Carcinoma In Situ (DCIS) 

        11.4.2.  Invasive Breast Cancer

            11.4.2.1. Invasive Ductal Carcinoma

            11.4.2.2.  Invasive Lobular Carcinoma

            11.4.2.3.  Metastatic Breast Cancer

            11.4.2.4.  Others

    11.5.  Market Value Forecast, by End-user, 2018–2028

        11.5.1. Hospitals & Ambulatory Surgery Centers

        11.5.2.  Diagnostic Laboratories

        11.5.3.  Research & Academic Institutes

    11.6.  Market Value Forecast, by Country/Sub-region, 2018–2028

        11.6.1. Germany

        11.6.2. U.K.

        11.6.3. France

        11.6.4. Italy

        11.6.5. Spain

        11.6.6. Rest of Europe

    11.7.  Market Attractiveness Analysis 

        11.7.1. By Technique 

        11.7.2.  By Cancer Type

        11.7.3.  By End-user

        11.7.4.  By Country/Sub-region

12. Asia Pacific Global Breast Cancer Diagnostics Market Analysis and Forecast

    12.1. Introduction

    12.2. Key Findings

    12.3. Market Value Forecast, by Technique, 2018–2028

        12.3.1. Imaging

            12.3.1.1. Mammography

                12.3.1.1.1. Analog Mammography

                12.3.1.1.2. Digital Mammography

            12.3.1.2. PET/CT Scan

        12.3.2. Tissue Biopsy Tests

        12.3.3.  Molecular Testing

    12.4.  Market Value Forecast, by Cancer Type, 2018–2028

        12.4.1. Ductal Carcinoma In Situ (DCIS) 

        12.4.2.  Invasive Breast Cancer

            12.4.2.1. Invasive Ductal Carcinoma

            12.4.2.2.  Invasive Lobular Carcinoma

            12.4.2.3.  Metastatic Breast Cancer

            12.4.2.4.  Others

    12.5.  Market Value Forecast, by End-user, 2018–2028

        12.5.1. Hospitals & Ambulatory Surgery Centers

        12.5.2.  Diagnostic Laboratories

        12.5.3.  Research & Academic Institutes

    12.6.  Market Value Forecast, by Country/Sub-region, 2018–2028

        12.6.1. China

        12.6.2. India

        12.6.3. Japan

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7.  Market Attractiveness Analysis 

        12.7.1. By Technique 

        12.7.2.  By Cancer Type

        12.7.3.  By End-user

        12.7.4.  By Country/Sub-region

13. Latin America Global Breast Cancer Diagnostics Market Analysis and Forecast

    13.1. Introduction

    13.2. Key Findings

    13.3. Market Value Forecast, by Technique, 2018–2028

        13.3.1. Imaging

            13.3.1.1. Mammography

                13.3.1.1.1. Analog Mammography

                13.3.1.1.2. Digital Mammography

            13.3.1.2. PET/CT Scan

        13.3.2. Tissue Biopsy Tests

        13.3.3.  Molecular Testing

    13.4.  Market Value Forecast, by Cancer Type, 2018–2028

        13.4.1. Ductal Carcinoma In Situ (DCIS) 

        13.4.2.  Invasive Breast Cancer

            13.4.2.1. Invasive Ductal Carcinoma

            13.4.2.2.  Invasive Lobular Carcinoma

            13.4.2.3.  Metastatic Breast Cancer

            13.4.2.4.  Others

    13.5.  Market Value Forecast, by End-user, 2018–2028

        13.5.1. Hospitals & Ambulatory Surgery Centers

        13.5.2.  Diagnostic Laboratories

        13.5.3.  Research & Academic Institutes

    13.6.  Market Value Forecast, by Country/Sub-region, 2018–2028

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7.  Market Attractiveness Analysis 

        13.7.1. By Technique 

        13.7.2.  By Cancer Type

        13.7.3.  By End-user

        13.7.4.  By Country/Sub-region

14. Middle East and Africa Global Breast Cancer Diagnostics Market Analysis and Forecast

    14.1. Introduction

    14.2. Key Findings

    14.3. Market Value Forecast, by Technique, 2018–2028

        14.3.1. Imaging

            14.3.1.1. Mammography

                14.3.1.1.1. Analog Mammography

                14.3.1.1.2. Digital Mammography

            14.3.1.2. PET/CT Scan

        14.3.2. Tissue Biopsy Tests

        14.3.3.  Molecular Testing

    14.4.  Market Value Forecast, by Cancer Type, 2018–2028

        14.4.1. Ductal Carcinoma In Situ (DCIS) 

        14.4.2.  Invasive Breast Cancer

            14.4.2.1. Invasive Ductal Carcinoma

            14.4.2.2.  Invasive Lobular Carcinoma

            14.4.2.3.  Metastatic Breast Cancer

            14.4.2.4.  Others

    14.5.  Market Value Forecast, by End-user, 2018–2028

        14.5.1. Hospitals & Ambulatory Surgery Centers

        14.5.2.  Diagnostic Laboratories

        14.5.3.  Research & Academic Institutes

    14.6.  Market Value Forecast, by Country/Sub-region, 2018–2028

        14.6.1. GCC

        14.6.2. South Africa

        14.6.3. Rest of Middle East & Africa

    14.7.  Market Attractiveness Analysis 

        14.7.1. By Technique 

        14.7.2.  By Cancer Type

        14.7.3.  By End-user

        14.7.4.  By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (By Tier and Size of companies)

    15.2. Market Share Analysis, by Company, 2018

    15.3.  Company Profiles

        15.3.1. Abbott Laboratories

                15.3.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.1.2. Product Portfolio

                15.3.1.1.3. SWOT Analysis

                15.3.1.1.4. Strategic Overview

        15.3.2.  GE Healthcare (General Electric Company)

                15.3.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.1.2. Product Portfolio

                15.3.2.1.3. SWOT Analysis

                15.3.2.1.4. Strategic Overview

        15.3.3.  Koninklijke Philips N.V.

                15.3.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.1.2. Product Portfolio

                15.3.3.1.3. SWOT Analysis

                15.3.3.1.4. Strategic Overview

        15.3.4.  Hologic, Inc.

                15.3.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.1.2. Product Portfolio

                15.3.4.1.3. SWOT Analysis

                15.3.4.1.4. Strategic Overview

        15.3.5.  C. R. Bard, Inc. (Becton, Dickinson and Company)

                15.3.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.1.2. Product Portfolio

                15.3.5.1.3. SWOT Analysis

                15.3.5.1.4. Strategic Overview

        15.3.6.  Siemens Healthineers (Siemens AG)

                15.3.6.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.1.2. Product Portfolio

                15.3.6.1.3. SWOT Analysis

                15.3.6.1.4. Strategic Overview

        15.3.7.  F. Hoffmann-La Roche Ltd.

                15.3.7.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.1.2. Product Portfolio

                15.3.7.1.3. SWOT Analysis

                15.3.7.1.4. Strategic Overview

        15.3.8.  Fujifilm Holding Corporation

                15.3.8.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.1.2. Product Portfolio

                15.3.8.1.3. SWOT Analysis

                15.3.8.1.4. Strategic Overview

        15.3.9.  Leica Biosystems Nussloch GmbH (Danaher)

                15.3.9.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.1.2. Product Portfolio

                15.3.9.1.3. SWOT Analysis

                15.3.9.1.4. Strategic Overview

        15.3.10. bioTheranostics, Inc.

                15.3.10.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.1.2. Product Portfolio

                15.3.10.1.3. SWOT Analysis

                15.3.10.1.4. Strategic Overview

        15.3.11. Myriad Genetics, Inc.

                15.3.11.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.1.2. Product Portfolio

                15.3.11.1.3. SWOT Analysis

                15.3.11.1.4. Strategic Overview

List of Tables

Table 01: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027

Table 02: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027

Table 03: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027

Table 04: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027

Table 05: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027

Table 06: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 07: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 08: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 09: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027

Table 10: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027

Table 11: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027

Table 12: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027

Table 13: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027

Table 14: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 15: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 16: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027

Table 17: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027

Table 18: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027

Table 19: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027

Table 20: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027

Table 21: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 22: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 23: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027

Table 24: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027

Table 25: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027

Table 26: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027

Table 27: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027

Table 28: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 29: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 30: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027

Table 31: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027

Table 32: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027

Table 33: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027

Table 34: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027

Table 35: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 36: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 37: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027

Table 38: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027

Table 39: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027

Table 40: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027

Table 41: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027

Table 42: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

List of Figures

Figure 01 Global Breast Cancer Diagnostics Market Value (US$ Mn), 2018 and 2027

Figure 02 Global Breast Cancer Diagnostics Market, Market Snapshot

Figure 03: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027

Figure 04: Global Breast Cancer Diagnostics Market Value Share, by Technique, 2018

Figure 05: Global Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018

Figure 06: Global Breast Cancer Diagnostics Market Value Share, by End-user, 2018

Figure 07: Global Breast Cancer Diagnostics Market Value Share, by Region, 2018

Figure 08: Global Breast Cancer Diagnostics Market Value Share, by Technique, 2018 and 2027

Figure 09: Global Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027

Figure 10: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Imaging, 2017–2027

Figure 11: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Tissue Biopsy Tests, 2017–2027

Figure 12: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Molecular Testing, 2017–2027

Figure 13: Global Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 14: Global Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 15: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ductal Carcinoma In Situ (DCIS), 2017–2027

Figure 16: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Invasive Breast Cancer, 2017–2027

Figure 17: Global Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 18: Global Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 19: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals & Ambulatory Surgery Center, 2017–2027

Figure 20: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diagnostic Laboratories, 2017–2027

Figure 21: Global Breast Cancer Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Research & Academic Institutes, 2017–2027

Figure 22: Global Breast Cancer Diagnostics Market Value Share, by Region, 2018 and 2027 

Figure 23: Global Breast Cancer Diagnostics Market Attractiveness Analysis, by Region, 2019–2027

Figure 24: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027

Figure 25: North America Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

Figure 26: North America Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027

Figure 27: North America Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027

Figure 28: North America Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027

Figure 29: North America Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 30: North America Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 31: North America Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 32: North America Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 33: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027

Figure 34: Europe Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

Figure 35: Europe Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027

Figure 36: Europe Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027

Figure 37: Europe Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027

Figure 38: Europe Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 39: Europe Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 40: Europe Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 41: Europe Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 42: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027

Figure 43: Asia Pacific Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

Figure 44: Asia Pacific Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027

Figure 45: Asia Pacific Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027

Figure 46: Asia Pacific Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027

Figure 47: Asia Pacific Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 48: Asia Pacific Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 49: Asia Pacific Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 50: Asia Pacific Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 51: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027

Figure 52: Latin America Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

Figure 53: Latin America Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027

Figure 54: Latin America Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027

Figure 55: Latin America Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027

Figure 56: Latin America Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 57: Latin America Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 58: Latin America Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 59: Latin America Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 60: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2027

Figure 61: Middle East & Africa Breast Cancer Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

Figure 62: Middle East & Africa Breast Cancer Diagnostics Market Attractiveness Analysis, by Country, 2019-2027

Figure 63: Middle East & Africa Breast Cancer Diagnostics Market Value Share Analysis, by Technique, 2018 and 2027

Figure 64: Middle East & Africa Breast Cancer Diagnostics Market Attractiveness Analysis, by Technique, 2019–2027

Figure 65: Middle East & Africa Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 66: Middle East & Africa Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 67: Middle East & Africa Breast Cancer Diagnostics Market Value Share, by Cancer Type, 2018 and 2027

Figure 68: Middle East & Africa Breast Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2019–2027

Figure 69: Global Breast Cancer Diagnostics Market Share Analysis, by Company, 2018

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

702

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved